Shots:

• Biogen has signed a letter of intent with Vir to develop & manufacture mAb targeting COVID-1 and have started working together due to the urgency of the crisis while a development & manufacturing agreement is being negotiated
• Following the completion of a definitive agreement- Biogen would continue cell line development- process development- and clinical manufacturing activities- advancing the development of Vir’s Abs
• Vir has identified several mAb targeting SARS-CoV-2- which were isolated from patients who had survived a SARS infection. The company is also evaluating its Abs as an effective treatment/ or prophylaxis against SARS-CoV-2

Click here ­to­ read full press release/ article 

| Ref: GlobeNewswire  | Image: Biogen